GET DAILY SIGNALSNeumora Therapeutics (NMRA) +18% Rebound in 30 Days: Pipeline Reset and Technical Bounce
Key Takeaways
- NMRA shares gained roughly 18% over the trailing 30 days, recovering from about $0.50 in early October to around $0.59 by early November.
- The move was led by a +35% single-session surge on November 2, 2026, on volume of roughly 5.8 million shares, far above the roughly 1.4–1.5 million daily average.
- The rebound followed a prolonged slide triggered by the June 2026 discontinuation of lead depression candidate navacaprant after three failed Phase 3 KOASTAL trials.
- Despite the 30-day advance, the stock remains down roughly 60% over the last quarter and far below its 52-week high of $3.65.
- Near-term catalysts include third-quarter 2026 results and expected fourth-quarter clinical readouts for NMRA-511, NMRA-898, and NMRA-215.
Company Background and Current Pipeline Focus
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, that applies a precision-neuroscience approach to brain diseases. Founded in 2019 and listed on Nasdaq in September 2023, the company develops oral, brain-penetrant small molecules targeting novel mechanisms for neuropsychiatric, neurodegenerative, and metabolic disorders. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Following the discontinuation of its former lead asset navacaprant, the pipeline now centers on three programs: NMRA-511, a vasopressin 1a receptor antagonist for agitation in Alzheimer's disease; NMRA-898, an M4 muscarinic receptor positive allosteric modulator for schizophrenia; and NMRA-215, an NLRP3 inhibitor for obesity and cardiometabolic disease. The company has no approved products or revenue, and investors follow the stock primarily for its binary clinical readouts and the optionality of its early-stage pipeline.
NMRA Stock Price Performance: Last 30 Days Versus the Quarter
Over the last 30 days, NMRA rose approximately 18%, from a close near $0.50 in early October to roughly $0.59 by early November. The path was highly volatile rather than linear: the shares slid to an intraday 52-week low of $0.3154 on October 14, recovered into the mid-$0.40s, and then retreated again before a sharp +35% rally on November 2 lifted the stock to $0.4957 on elevated volume.
The near-term bounce contrasts sharply with the longer trend. Over the last quarter, the stock is down roughly 60%, falling from about $1.60 in early August to under $0.60 currently. This multi-month decline reflects the ongoing de-rating of the business after the loss of its lead clinical program, offset only recently by a rebound from deeply oversold levels.
Drivers Behind the Recent 30-Day Advance
The 30-day gain was driven less by a single fundamental announcement than by a sharp technical rebound from capitulation-level prices. After shares broke below $0.35 in mid-October, sellers appeared exhausted, and the stock staged a recovery into early November. The November 2 surge of roughly 35% occurred on roughly four times the average volume, a pattern consistent with short covering and repositioning ahead of known catalysts. From what I see, this volume profile often signals potential exhaustion of selling pressure.
Those catalysts are concrete. Neumora was scheduled to report third-quarter 2026 results in early November, with consensus expectations around a net loss of roughly $0.19 to $0.21 per share. Management has also guided to multiple fourth-quarter 2026 data events, including the NMRA-511 multiple-ascending-dose readout in Alzheimer's disease agitation, Phase 1 data for NMRA-898 in schizophrenia, and the planned IND submission and clinical entry for NMRA-215. Anticipation of these updates, combined with the stock's depressed valuation, helped fuel the rebound.
Factors Behind the Broader Quarterly Decline
The quarterly decline is rooted in the company's June 2026 decision to discontinue navacaprant, a kappa opioid receptor antagonist, after the Phase 3 KOASTAL-2 and KOASTAL-3 studies failed to beat placebo in major depressive disorder. That outcome followed the earlier KOASTAL-1 miss and removed the company's most advanced and closely watched asset.
In response, Neumora cut its workforce by roughly 35% to deliver about $10 million in annualized cost savings, and it refocused resources on NMRA-511, NMRA-898, and NMRA-215. The shares continued to grind lower through the summer and early fall as the market reassessed a now earlier-stage pipeline. A Nasdaq non-compliance notice related to the sub-$1.00 share price added to the overhang, even as the company's cash position of roughly $116.8 million supports a runway into the third quarter of 2027.
Key Developments to Monitor Ahead
Several factors will shape NMRA over the coming months. Third-quarter 2026 earnings and updated cash-burn guidance will clarify the pace of spending after the restructuring. The most consequential events are clinical: the NMRA-511 multiple-ascending-dose results, NMRA-898 Phase 1 data, and the advancement of NMRA-215 toward the clinic, all guided for late 2026. I’m watching this closely because these readouts could reset sentiment quickly.
Investors should also monitor the Nasdaq listing-compliance timeline, as the shares remain below the $1.00 threshold and must sustain a higher level to avoid delisting risk. Wall Street coverage remains generally constructive, with several analysts maintaining Buy or Outperform ratings and 12-month price targets in the $3.00 to $7.00 range, though these targets embed substantial clinical and financing risk. As a pre-revenue biotech with no approved products, Neumora's valuation will remain sensitive to trial outcomes, capital needs, and competitive developments in the CNS and metabolic spaces.
Using AI Tools for Biotech Research
In my own process, I often turn to Tickeron’s AI Trading Bots to test systematic approaches on volatile names like this one. The platform lets me review a range of automated strategies, compare performance across different holding periods, and see how they align with upcoming catalysts. It provides a practical way to supplement fundamental work with data-driven signals without replacing personal judgment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
NMRA in +55.47% Uptrend, growing for three consecutive days on November 03, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NMRA advanced for three days, in 146 of 167 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NMRA's RSI Oscillator exited the oversold zone, 18 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 27 of 31 cases where NMRA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on NMRA as a result. In 42 of 50 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for NMRA just turned positive on October 08, 2026. Looking at past instances where NMRA's MACD turned positive, the stock continued to rise in 17 of 20 cases over the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NMRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
NMRA broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NMRA entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.410) is normal, around the industry mean (3.051). P/E Ratio (-0.464) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. NMRA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NMRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement